The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More
News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW. This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More
Antiretroviral therapy (ART) against HIV may have altered the course of human evolution, research says. A study led by researchers at the University of Oxford, published in Proceedings of the National Academy of Sciences (PNAS), shows that ART is not only transforming outcomes for people living with… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More
News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW. This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research. The top stories: … Read More
An injectable treatment for HIV could be more effective than a daily oral therapy, data suggests. Results from the LATITUDE study of Cabenuva (cabotegravir + rilpivirine), a long-acting injectable developed by HIV specialist ViiV Healthcare, show the switch to the injectable reduced risk of virological failure by nearly half compared to… Read More
News round-up for 4-8 August by DDW Senior Digital Content Editor Diana Turner. In the week that the US Department of Health and Human Services cancelled multiple programmes investigating mRNA vaccines, a number of other clinical trials have made the headlines. The top stories:… Read More
A Phase I clinical trial of a novel T cell-inducing HIV vaccine candidate has launched in Africa to evaluate immune responses to highly networked HIV T-cell epitopes. The trial is a collaboration between The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT,… Read More
Gilead Sciences will share new Phase III trial data showing that twice-yearly lenacapavir (Yeztugo) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention. The new data, from the company’s pivotal Phase III PURPOSE 1 and… Read More
Researchers from the Peter Doherty Institute for Infection and Immunity in Melbourne have demonstrated a way to make HIV visible, paving the way to a complete cure. In a paper published in Nature Communications, the scientists have shown for the first time that… Read More
Several companies shared new trial data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, US. Once-yearly lenacapavir for HIV prevention Gilead Sciences presented the first data from its ongoing Phase I study investigating two once-yearly formulations of lenacapavir, an injectable HIV-1 capsid… Read More
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first generic raltegravir drug to treat adult and paediatric HIV patients who weigh at least 40kg. HIV produces an enzyme called HIV integrase which enables multiplication of the virus in cells within the body. Read More
Interim analysis of the Phase III PURPOSE 1 trial indicates that Gilead Sciences twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrates 100% efficacy for the investigational use of HIV prevention in cisgender women. PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily… Read More
Drugs developed to treat HIV and AIDS are being trialled for the first time in patients with multiple brain tumours. Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, ritonavir… Read More
Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with… Read More
Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies – a human broadly neutralsing antibody and two antibodies isolated from previously vaccinated monkeys – target… Read More
